(Reuters) - A federal judge ruled on Tuesday that some
product-liability claims against Boston Scientific over
implantable heart defibrillators, which regulate abnormal
heartbeats, can proceed to trial, rejecting the company's
motions to dismiss them. For details, see [ID:nN13335046]
Guidant Corp., which Boston Scientific bought last year,
continued to sell heart rhythm-management devices after
learning of possible defects, a U.S. District Court judge in
Minnesota said in the ruling.
Read more at Reuters.com Bonds News
product-liability claims against Boston Scientific over
implantable heart defibrillators, which regulate abnormal
heartbeats, can proceed to trial, rejecting the company's
motions to dismiss them. For details, see [ID:nN13335046]
Guidant Corp., which Boston Scientific bought last year,
continued to sell heart rhythm-management devices after
learning of possible defects, a U.S. District Court judge in
Minnesota said in the ruling.
Read more at Reuters.com Bonds News
No comments:
Post a Comment